CN116271199A - Liquid adhesive bandage and preparation method thereof - Google Patents
Liquid adhesive bandage and preparation method thereof Download PDFInfo
- Publication number
- CN116271199A CN116271199A CN202211091707.9A CN202211091707A CN116271199A CN 116271199 A CN116271199 A CN 116271199A CN 202211091707 A CN202211091707 A CN 202211091707A CN 116271199 A CN116271199 A CN 116271199A
- Authority
- CN
- China
- Prior art keywords
- parts
- film forming
- agent
- adhesive
- forming agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000853 adhesive Substances 0.000 title claims abstract description 112
- 230000001070 adhesive effect Effects 0.000 title claims abstract description 112
- 239000007788 liquid Substances 0.000 title claims abstract description 67
- 238000002360 preparation method Methods 0.000 title abstract description 10
- 239000002904 solvent Substances 0.000 claims abstract description 48
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 44
- 239000004014 plasticizer Substances 0.000 claims abstract description 31
- 239000000645 desinfectant Substances 0.000 claims abstract description 29
- 238000000034 method Methods 0.000 claims abstract description 14
- 239000013003 healing agent Substances 0.000 claims abstract description 12
- 239000000049 pigment Substances 0.000 claims abstract description 4
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 claims description 32
- 239000004925 Acrylic resin Substances 0.000 claims description 29
- 238000002156 mixing Methods 0.000 claims description 25
- 239000010677 tea tree oil Substances 0.000 claims description 20
- 229940111630 tea tree oil Drugs 0.000 claims description 20
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 claims description 19
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 18
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 16
- 239000001087 glyceryl triacetate Substances 0.000 claims description 16
- 235000013773 glyceryl triacetate Nutrition 0.000 claims description 16
- 239000000741 silica gel Substances 0.000 claims description 16
- 229960002622 triacetin Drugs 0.000 claims description 16
- CFKMVGJGLGKFKI-UHFFFAOYSA-N 4-chloro-m-cresol Chemical compound CC1=CC(O)=CC=C1Cl CFKMVGJGLGKFKI-UHFFFAOYSA-N 0.000 claims description 12
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 claims description 12
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 claims description 12
- 229960003237 betaine Drugs 0.000 claims description 12
- UAUDZVJPLUQNMU-KTKRTIGZSA-N erucamide Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCC(N)=O UAUDZVJPLUQNMU-KTKRTIGZSA-N 0.000 claims description 12
- UAUDZVJPLUQNMU-UHFFFAOYSA-N Erucasaeureamid Natural products CCCCCCCCC=CCCCCCCCCCCCC(N)=O UAUDZVJPLUQNMU-UHFFFAOYSA-N 0.000 claims description 11
- -1 polyhexamethylene monoguanidine hydrochloride Polymers 0.000 claims description 11
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 10
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 10
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 10
- 229920006316 polyvinylpyrrolidine Polymers 0.000 claims description 9
- DZGUJOWBVDZNNF-UHFFFAOYSA-N azanium;2-methylprop-2-enoate Chemical compound [NH4+].CC(=C)C([O-])=O DZGUJOWBVDZNNF-UHFFFAOYSA-N 0.000 claims description 8
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 7
- 229960002233 benzalkonium bromide Drugs 0.000 claims description 7
- KHSLHYAUZSPBIU-UHFFFAOYSA-M benzododecinium bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 KHSLHYAUZSPBIU-UHFFFAOYSA-M 0.000 claims description 7
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 7
- 239000000194 fatty acid Substances 0.000 claims description 7
- 229930195729 fatty acid Natural products 0.000 claims description 7
- 150000004665 fatty acids Chemical class 0.000 claims description 7
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims description 7
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 claims description 7
- MQIUGAXCHLFZKX-UHFFFAOYSA-N Di-n-octyl phthalate Natural products CCCCCCCCOC(=O)C1=CC=CC=C1C(=O)OCCCCCCCC MQIUGAXCHLFZKX-UHFFFAOYSA-N 0.000 claims description 6
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 claims description 6
- 238000006243 chemical reaction Methods 0.000 claims description 6
- 229960002242 chlorocresol Drugs 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 6
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 5
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 claims description 5
- 229960000686 benzalkonium chloride Drugs 0.000 claims description 5
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 5
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 5
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 5
- 229940105329 carboxymethylcellulose Drugs 0.000 claims description 5
- 235000019359 magnesium stearate Nutrition 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- 239000012747 synergistic agent Substances 0.000 claims description 5
- 239000001069 triethyl citrate Substances 0.000 claims description 5
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 claims description 5
- 235000013769 triethyl citrate Nutrition 0.000 claims description 5
- 239000000341 volatile oil Substances 0.000 claims description 5
- WTVHAMTYZJGJLJ-UHFFFAOYSA-N (+)-(4S,8R)-8-epi-beta-bisabolol Natural products CC(C)=CCCC(C)C1(O)CCC(C)=CC1 WTVHAMTYZJGJLJ-UHFFFAOYSA-N 0.000 claims description 4
- RGZSQWQPBWRIAQ-CABCVRRESA-N (-)-alpha-Bisabolol Chemical compound CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-CABCVRRESA-N 0.000 claims description 4
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 4
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 4
- 239000000020 Nitrocellulose Substances 0.000 claims description 4
- FJWGYAHXMCUOOM-QHOUIDNNSA-N [(2s,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6s)-4,5-dinitrooxy-2-(nitrooxymethyl)-6-[(2r,3r,4s,5r,6s)-4,5,6-trinitrooxy-2-(nitrooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dinitrooxy-6-(nitrooxymethyl)oxan-4-yl] nitrate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O)O[C@H]1[C@@H]([C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@@H](CO[N+]([O-])=O)O1)O[N+]([O-])=O)CO[N+](=O)[O-])[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O FJWGYAHXMCUOOM-QHOUIDNNSA-N 0.000 claims description 4
- RGZSQWQPBWRIAQ-LSDHHAIUSA-N alpha-Bisabolol Natural products CC(C)=CCC[C@@](C)(O)[C@@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-LSDHHAIUSA-N 0.000 claims description 4
- 229940036350 bisabolol Drugs 0.000 claims description 4
- HHGZABIIYIWLGA-UHFFFAOYSA-N bisabolol Natural products CC1CCC(C(C)(O)CCC=C(C)C)CC1 HHGZABIIYIWLGA-UHFFFAOYSA-N 0.000 claims description 4
- 229920001400 block copolymer Polymers 0.000 claims description 4
- DOIRQSBPFJWKBE-UHFFFAOYSA-N dibutyl phthalate Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 claims description 4
- FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 claims description 4
- 229940071826 hydroxyethyl cellulose Drugs 0.000 claims description 4
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 4
- 229920001220 nitrocellulos Polymers 0.000 claims description 4
- 229940079938 nitrocellulose Drugs 0.000 claims description 4
- 229920002554 vinyl polymer Polymers 0.000 claims description 4
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims description 3
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 3
- OSDLLIBGSJNGJE-UHFFFAOYSA-N 4-chloro-3,5-dimethylphenol Chemical compound CC1=CC(O)=CC(C)=C1Cl OSDLLIBGSJNGJE-UHFFFAOYSA-N 0.000 claims description 3
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 claims description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims description 3
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 claims description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 3
- OJIYIVCMRYCWSE-UHFFFAOYSA-M Domiphen bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)CCOC1=CC=CC=C1 OJIYIVCMRYCWSE-UHFFFAOYSA-M 0.000 claims description 3
- 229920002907 Guar gum Polymers 0.000 claims description 3
- 229920002413 Polyhexanide Polymers 0.000 claims description 3
- 229920001800 Shellac Polymers 0.000 claims description 3
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 claims description 3
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 3
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 3
- 229960000458 allantoin Drugs 0.000 claims description 3
- 239000010684 cajeput oil Substances 0.000 claims description 3
- 229960003260 chlorhexidine Drugs 0.000 claims description 3
- 229920001577 copolymer Polymers 0.000 claims description 3
- 229960001859 domiphen bromide Drugs 0.000 claims description 3
- 239000000665 guar gum Substances 0.000 claims description 3
- 235000010417 guar gum Nutrition 0.000 claims description 3
- 229960002154 guar gum Drugs 0.000 claims description 3
- SLKWROUNLHVIIQ-UHFFFAOYSA-N hexachlorocyclohexa-2,5-dien-1-one Chemical compound ClC1=C(Cl)C(Cl)(Cl)C(Cl)=C(Cl)C1=O SLKWROUNLHVIIQ-UHFFFAOYSA-N 0.000 claims description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 3
- 229920000609 methyl cellulose Polymers 0.000 claims description 3
- 239000001923 methylcellulose Substances 0.000 claims description 3
- 229960002900 methylcellulose Drugs 0.000 claims description 3
- 235000010981 methylcellulose Nutrition 0.000 claims description 3
- 229920002037 poly(vinyl butyral) polymer Polymers 0.000 claims description 3
- 239000004208 shellac Substances 0.000 claims description 3
- 229940113147 shellac Drugs 0.000 claims description 3
- 235000013874 shellac Nutrition 0.000 claims description 3
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 claims description 3
- 229910002027 silica gel Inorganic materials 0.000 claims description 3
- 229960003500 triclosan Drugs 0.000 claims description 3
- 235000019155 vitamin A Nutrition 0.000 claims description 3
- 239000011719 vitamin A Substances 0.000 claims description 3
- 229940045997 vitamin a Drugs 0.000 claims description 3
- 239000000230 xanthan gum Substances 0.000 claims description 3
- 229920001285 xanthan gum Polymers 0.000 claims description 3
- 235000010493 xanthan gum Nutrition 0.000 claims description 3
- 229940082509 xanthan gum Drugs 0.000 claims description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 2
- QZCLKYGREBVARF-UHFFFAOYSA-N Acetyl tributyl citrate Chemical compound CCCCOC(=O)CC(C(=O)OCCCC)(OC(C)=O)CC(=O)OCCCC QZCLKYGREBVARF-UHFFFAOYSA-N 0.000 claims description 2
- 244000131316 Panax pseudoginseng Species 0.000 claims description 2
- 235000003181 Panax pseudoginseng Nutrition 0.000 claims description 2
- 244000086363 Pterocarpus indicus Species 0.000 claims description 2
- 235000009984 Pterocarpus indicus Nutrition 0.000 claims description 2
- BJQHLKABXJIVAM-UHFFFAOYSA-N bis(2-ethylhexyl) phthalate Chemical compound CCCCC(CC)COC(=O)C1=CC=CC=C1C(=O)OCC(CC)CCCC BJQHLKABXJIVAM-UHFFFAOYSA-N 0.000 claims description 2
- ZFMQKOWCDKKBIF-UHFFFAOYSA-N bis(3,5-difluorophenyl)phosphane Chemical compound FC1=CC(F)=CC(PC=2C=C(F)C=C(F)C=2)=C1 ZFMQKOWCDKKBIF-UHFFFAOYSA-N 0.000 claims description 2
- 229940038879 chelated zinc Drugs 0.000 claims description 2
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 2
- 239000010642 eucalyptus oil Substances 0.000 claims description 2
- 229940044949 eucalyptus oil Drugs 0.000 claims description 2
- 229940075529 glyceryl stearate Drugs 0.000 claims description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 claims description 2
- JQCXWCOOWVGKMT-UHFFFAOYSA-N phthalic acid diheptyl ester Natural products CCCCCCCOC(=O)C1=CC=CC=C1C(=O)OCCCCCCC JQCXWCOOWVGKMT-UHFFFAOYSA-N 0.000 claims description 2
- 239000002023 wood Substances 0.000 claims description 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims 1
- PQPVPZTVJLXQAS-UHFFFAOYSA-N hydroxy-methyl-phenylsilicon Chemical compound C[Si](O)C1=CC=CC=C1 PQPVPZTVJLXQAS-UHFFFAOYSA-N 0.000 claims 1
- 238000004659 sterilization and disinfection Methods 0.000 abstract description 23
- 230000035699 permeability Effects 0.000 abstract description 22
- 241000894006 Bacteria Species 0.000 abstract description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 17
- 230000001954 sterilising effect Effects 0.000 abstract description 11
- 241001465754 Metazoa Species 0.000 abstract description 7
- 230000009471 action Effects 0.000 abstract description 7
- 230000008569 process Effects 0.000 abstract description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 63
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 52
- 229920002472 Starch Polymers 0.000 description 33
- 239000008107 starch Substances 0.000 description 33
- 235000019698 starch Nutrition 0.000 description 33
- 230000000052 comparative effect Effects 0.000 description 27
- 229960003638 dopamine Drugs 0.000 description 26
- 108010010803 Gelatin Proteins 0.000 description 25
- 239000008273 gelatin Substances 0.000 description 25
- 229920000159 gelatin Polymers 0.000 description 25
- 235000019322 gelatine Nutrition 0.000 description 25
- 235000011852 gelatine desserts Nutrition 0.000 description 25
- 238000012360 testing method Methods 0.000 description 24
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 20
- 229920000193 polymethacrylate Polymers 0.000 description 20
- 206010052428 Wound Diseases 0.000 description 19
- 208000027418 Wounds and injury Diseases 0.000 description 19
- 210000003491 skin Anatomy 0.000 description 19
- SGHZXLIDFTYFHQ-UHFFFAOYSA-L Brilliant Blue Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 SGHZXLIDFTYFHQ-UHFFFAOYSA-L 0.000 description 17
- 239000001055 blue pigment Substances 0.000 description 17
- 229910021487 silica fume Inorganic materials 0.000 description 13
- 230000000694 effects Effects 0.000 description 12
- 230000001580 bacterial effect Effects 0.000 description 11
- 239000003814 drug Substances 0.000 description 11
- 239000003242 anti bacterial agent Substances 0.000 description 8
- 208000015181 infectious disease Diseases 0.000 description 8
- NHTMVDHEPJAVLT-UHFFFAOYSA-N Isooctane Chemical compound CC(C)CC(C)(C)C NHTMVDHEPJAVLT-UHFFFAOYSA-N 0.000 description 7
- JVSWJIKNEAIKJW-UHFFFAOYSA-N dimethyl-hexane Natural products CCCCCC(C)C JVSWJIKNEAIKJW-UHFFFAOYSA-N 0.000 description 7
- UQEAIHBTYFGYIE-UHFFFAOYSA-N hexamethyldisiloxane Chemical compound C[Si](C)(C)O[Si](C)(C)C UQEAIHBTYFGYIE-UHFFFAOYSA-N 0.000 description 7
- 239000007921 spray Substances 0.000 description 7
- 241000283690 Bos taurus Species 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 230000035876 healing Effects 0.000 description 6
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 239000004094 surface-active agent Substances 0.000 description 5
- PSBDWGZCVUAZQS-UHFFFAOYSA-N (dimethylsulfonio)acetate Chemical compound C[S+](C)CC([O-])=O PSBDWGZCVUAZQS-UHFFFAOYSA-N 0.000 description 4
- GTQHJCOHNAFHRE-UHFFFAOYSA-N 1,10-dibromodecane Chemical compound BrCCCCCCCCCCBr GTQHJCOHNAFHRE-UHFFFAOYSA-N 0.000 description 4
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 4
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 4
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 229920000153 Povidone-iodine Polymers 0.000 description 4
- XIWFQDBQMCDYJT-UHFFFAOYSA-M benzyl-dimethyl-tridecylazanium;chloride Chemical compound [Cl-].CCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 XIWFQDBQMCDYJT-UHFFFAOYSA-M 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 229940044519 poloxamer 188 Drugs 0.000 description 4
- 229920001993 poloxamer 188 Polymers 0.000 description 4
- 229960001621 povidone-iodine Drugs 0.000 description 4
- 238000005507 spraying Methods 0.000 description 4
- 229940117986 sulfobetaine Drugs 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 208000035143 Bacterial infection Diseases 0.000 description 3
- 241000222122 Candida albicans Species 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229920002507 Poloxamer 124 Polymers 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 206010040880 Skin irritation Diseases 0.000 description 3
- 206010072170 Skin wound Diseases 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 208000022362 bacterial infectious disease Diseases 0.000 description 3
- 229940095731 candida albicans Drugs 0.000 description 3
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 210000000003 hoof Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229940093448 poloxamer 124 Drugs 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 230000036556 skin irritation Effects 0.000 description 3
- 231100000475 skin irritation Toxicity 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- SYBYTAAJFKOIEJ-UHFFFAOYSA-N 3-Methylbutan-2-one Chemical compound CC(C)C(C)=O SYBYTAAJFKOIEJ-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 2
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 2
- 229920002511 Poloxamer 237 Polymers 0.000 description 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- XNLICIUVMPYHGG-UHFFFAOYSA-N pentan-2-one Chemical compound CCCC(C)=O XNLICIUVMPYHGG-UHFFFAOYSA-N 0.000 description 2
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 2
- 238000011056 performance test Methods 0.000 description 2
- 239000011505 plaster Substances 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 230000005808 skin problem Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical group CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 1
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 description 1
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 1
- OAYXUHPQHDHDDZ-UHFFFAOYSA-N 2-(2-butoxyethoxy)ethanol Chemical compound CCCCOCCOCCO OAYXUHPQHDHDDZ-UHFFFAOYSA-N 0.000 description 1
- DXCXWVLIDGPHEA-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-3-[(4-ethylpiperazin-1-yl)methyl]pyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C(=NN(C=1)CC(=O)N1CC2=C(CC1)NN=N2)CN1CCN(CC1)CC DXCXWVLIDGPHEA-UHFFFAOYSA-N 0.000 description 1
- 229920000178 Acrylic resin Polymers 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 235000003143 Panax notoginseng Nutrition 0.000 description 1
- 241000180649 Panax notoginseng Species 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000241413 Propolis Species 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 238000005411 Van der Waals force Methods 0.000 description 1
- JAWMENYCRQKKJY-UHFFFAOYSA-N [3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-ylmethyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-en-8-yl]-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]methanone Chemical compound N1N=NC=2CN(CCC=21)CC1=NOC2(C1)CCN(CC2)C(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F JAWMENYCRQKKJY-UHFFFAOYSA-N 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- 150000001241 acetals Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229940116229 borneol Drugs 0.000 description 1
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 description 1
- 208000034526 bruise Diseases 0.000 description 1
- 239000013590 bulk material Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000007334 copolymerization reaction Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 description 1
- TVACALAUIQMRDF-UHFFFAOYSA-N dodecyl dihydrogen phosphate Chemical compound CCCCCCCCCCCCOP(O)(O)=O TVACALAUIQMRDF-UHFFFAOYSA-N 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 239000008233 hard water Substances 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 1
- 229940011051 isopropyl acetate Drugs 0.000 description 1
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 229960003639 laurocapram Drugs 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- RNTIBYGPJVJCCJ-UHFFFAOYSA-N n,n-dimethylmethanamine;ethyl 2-methylprop-2-enoate Chemical compound CN(C)C.CCOC(=O)C(C)=C RNTIBYGPJVJCCJ-UHFFFAOYSA-N 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
- 125000006353 oxyethylene group Chemical group 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 229940069949 propolis Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000004706 scrotum Anatomy 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 229940045920 sodium pyrrolidone carboxylate Drugs 0.000 description 1
- HYRLWUFWDYFEES-UHFFFAOYSA-M sodium;2-oxopyrrolidine-1-carboxylate Chemical compound [Na+].[O-]C(=O)N1CCCC1=O HYRLWUFWDYFEES-UHFFFAOYSA-M 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 238000004804 winding Methods 0.000 description 1
- 239000003357 wound healing promoting agent Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000002888 zwitterionic surfactant Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/0066—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0014—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0023—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/45—Mixtures of two or more drugs, e.g. synergistic mixtures
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/602—Type of release, e.g. controlled, sustained, slow
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
The invention discloses a liquid adhesive bandage and a preparation method thereof, and belongs to the technical field of medical appliances. Comprises 5-15 parts of film forming agent, 0.1-5 parts of disinfectant, 0-5 parts of plasticizer, 0-3 parts of anti-adhesion agent, 1-5 parts of healing agent, 0.1-0.5 part of adhesive, 0.01-0.05 part of synergist, 0-0.5 part of pigment and the balance of solvent. The film forming agent selected by the liquid adhesive bandage can quickly generate a layer of breathable waterproof film which is tightly attached to the skin at a using position, meanwhile, the plasticizer is added, the elasticity and toughness of the film are improved, the distortion resistance is high in the moving process of people or animals, the adhesive bandage film is not cracked due to actions, the skin friendly adhesive is added, the film forming viscosity is greatly improved, the falling off is prevented, the film forming agent does not have dry and tight feel after being used, and compared with products on the market, the film forming agent has high film forming speed, and has better flex resistance, cohesiveness, water resistance, air permeability, sterilization property and bacteria resistance.
Description
Technical Field
The invention relates to the technical field of medical appliances, in particular to a liquid wound plaster for disinfecting the surface of damaged skin and a preparation method thereof.
Background
Skin surface small wounds caused by bruise, incised wound, lacerated wound, mild scald, bacterial infection, fungal infection and the like are common skin problems in life, and people usually use wound adhesives to treat the wounds so as to achieve the purposes of hemostasis by compression, wound protection, infection prevention and healing promotion. The common adhesive bandage has poor air permeability, water vapor and sweat secreted by human bodies cannot penetrate, bacteria are easy to grow and reproduce, and skin at a wound is whitened to cause subsequent infection; second, most conventional bandages are of a fixed size and dimensions and are not suitable for wounds of various sizes. However, animals such as cows also have problems of skin wounds and infections, such as hoof diseases caused by bacterial infection of cows, which cause discomfort to the cows, cause emotion, reduce milk yield, and even cause other diseases to cause death of the cows. These animal skin problems cannot be met with existing solid bandages to prevent infection, while liquid bandages can solve the problem.
The existing liquid band-aid is generally composed of a film forming agent and disinfection components, so that the external infection sources are isolated while disinfection and sterilization are achieved. The liquid band-aid disclosed in publication No. CN105797202A comprises a film forming component, a plasticizer and a solvent, wherein the film forming component is polyacrylic resin, and the medicinal component is menthol, so that the liquid band-aid has the effects of diminishing inflammation, relieving pain and relieving itching. However, the technical proposal does not add the components which are high-efficiency and fast sterilization. Publication No. CN110251720A discloses a liquid dressing and a preparation method thereof, wherein 5-12 parts of eight-profile film forming agent I, 0-8 parts of film forming agent II, 50-90 parts of volatile solvent and 1-10 parts of plasticizer. The film forming agent I is selected from polyvinyl acetal, and the film forming agent II is selected from ethyl cellulose, nitrocellulose, polyvinylpyrrolidone, polydimethylsiloxane and polyacrylic resin. The technical proposal does not adopt medicinal components with high-efficiency sterilization and disinfection. The efficient liquid adhesive bandage disclosed in publication No. CN113413373A comprises 20-30 parts of modified nitrocellulose-acrylic resin polymer powder (film forming agent), 1-3 parts of propolis, 1-3 parts of polyvinyl alcohol, 0.01-0.1 part of cetostearyl alcohol, 0.01-0.1 part of sodium pyrrolidone carboxylate, 0.01-0.1 part of plasticizer, 0.01-0.1 part of monolauryl phosphate, 0.05-0.1 part of laurocapram, 0.1-0.2 part of borneol, 0.01-0.1 part of pharmaceutical active ingredient, 30-40 parts of ethanol and 5-10 parts of deionized water. Therefore, the existing liquid adhesive bandage forms a film on the surface of the skin through the film forming agent to block external infection sources from entering the skin, thereby achieving the purposes of protecting the wound surface and preventing infection. However, the existing liquid band-aid is not provided with high-efficiency sterilization, antibiosis and antiphlogosis products, only the single effects of water resistance and infection prevention can be realized, and the functions of quick sterilization and healing promotion cannot be realized.
The water-based polyurethane liquid dressing disclosed in publication No. CN114057982A, a preparation method thereof and an antibacterial film layer are provided, wherein an antibacterial agent is added, and the antibacterial agent is one of a quaternary ammonium salt antibacterial agent, a guanidine antibacterial agent and a natural antibacterial agent. A wound spray for treating abrasion and a preparation method thereof are disclosed in publication number CN102772801a, wherein the wound spray comprises functional components and a film forming component, the functional components comprise disinfectant, antibiotics, anesthetic and the like, and the film forming agent is mainly ethylcellulose. In the technical scheme, the antibacterial agent and the medicinal components are added into the film forming component, but some film forming components have slower film forming speed to influence the use, and some film forming components have weak viscosity, and have low flexibility resistance and are easy to fall off to influence the antibacterial use in daily activities.
Disclosure of Invention
In order to solve the problems, the liquid adhesive bandage has the advantages of high film forming speed, high viscosity, good air permeability and high flexibility resistance after film forming, and can be used for quickly healing skin wounds by being provided with disinfection components and wound healing agents.
The invention also discloses a preparation method of the liquid adhesive bandage.
In order to achieve the above object, the present invention is achieved by the following technical scheme:
a liquid adhesive bandage comprises 5-15 parts of film forming agent, 0.1-5 parts of disinfectant, 0-5 parts of plasticizer, 0-3 parts of anti-adhesion agent, 1-5 parts of healing agent, 0.1-0.5 part of adhesive, 0.01-0.05 part of synergist, 0-0.5 part of pigment and the balance of solvent.
Further, the film forming agent is one or more of ammonium methacrylate I, ammonium methacrylate II, polyacrylic resin III, polyvinylpyrrolidone K15, polyvinylpyrrolidone K30, polyvinylpyrrolidone K60, polyvinyl alcohol 05-88, polyvinyl alcohol 17-88, polyvinyl alcohol 124, polyvinyl formal, polyvinyl butyral, methylcellulose, hydroxypropyl methylcellulose, hydroxyethyl cellulose, carboxymethyl cellulose, nitrocellulose, xanthan gum, guar gum and shellac.
Preferably, the film forming agent of the present invention comprises at least polyacrylic resin II or polyacrylic resin III.
Preferably, the film forming agent of the present invention comprises at least ammonium polymethacrylate I or ammonium polymethacrylate II.
Further, the disinfectant comprises one or more of iodine, triclosan, parachlorometaxylenol, chlorocresol, hexachlorophenol, polyhexamethylene monoguanidine hydrochloride, polyhexamethylene biguanide hydrochloride, chlorhexidine, benzalkonium chloride, benzalkonium bromide, decamethenamine chloride, decamethenamine bromide and domiphen bromide.
Further, the plasticizer is one or more of triethyl citrate, triacetin, acetyl tributyl citrate, dioctyl adipate, diethyl phthalate, dibutyl phthalate, dioctyl phthalate, butyl Jizhi phthalate, di-n-octyl phthalate and polyethyl benzyl siloxane.
Further, the healing agent is one or more of cajeput oil, benzyl alcohol, bisabolol, tea tree oil, permanent flower essential oil, eucalyptus oil, pseudo-ginseng, rosewood heart wood, allantoin, vitamin A and chelated zinc.
Further, the anti-sticking agent is one or more of talcum powder, magnesium stearate, micro silica gel and glyceryl stearate.
Further, the adhesive comprises any one or more of gelatin, dopamine, starch, cellulose and hyperbranched polyglycidyl ether. Wherein the starch is hyperbranched starch.
Preferably, the adhesive of the invention comprises gelatin, dopamine and hyperbranched starch mixed according to the ratio of 4 (0.5-1) to 1-2.
Further, the synergistic agent is a surfactant and comprises any one or a mixture of more than one of polyoxyethylene polyoxypropylene ether block copolymer, polyoxyethylene fatty acid, erucic acid amide betaine and acrylamide sulfobetaine.
Further, the average molecular weight of the polyoxyethylene polyoxypropylene ether block copolymer is 1100-11000.
Preferably, the polyoxyethylene polyoxypropylene ether block copolymer in the synergistic agent is any one of poloxamer 124, poloxamer 188 and poloxamer 237. Poloxamers are nonionic polymeric surfactants, the surface activity of which is related to structure. The poloxamer selected by the invention has the advantages of higher oxyethylene chain segment proportion, higher HLB value, stronger hydrophilicity, better wettability and permeability, and capability of enabling the liquid adhesive bandage to be rapidly spread on skin and better ductility, so that the liquid adhesive bandage can be rapidly formed into a film.
Further, the solvent is one or more of isooctane, hexamethyldisiloxane, methanol, ethanol, isopropanol, propanol, propylene glycol, glycerol, diethylene glycol, acetone, ethyl acetate, diethylene glycol butyl ether, methyl n-propyl ketone, isopropyl acetate, methyl ethyl ketone, methyl isopropyl ketone, tetrahydrofuran, isooctane, hexamethyldisiloxane and water.
More preferably, the solvent is isooctane mixed with ethanol in a ratio of 1 (1-10).
More preferably, the solvent is hexamethyldisiloxane and ethanol are mixed in a ratio of 1 (5-10).
The solvent selected by the invention has high volatility, and the solvent coated on the surface of the skin volatilizes rapidly, so that the film forming speed is higher, and the film forming speed can be improved to 30-60s.
The film forming agent is prepared by compounding ammonium polymethacrylate and polyacrylic resin, and the polyacrylic resin is solidified on the surface of skin to form a protective film.
The invention adds the adhesive, the adhesive contains hyperbranched starch, and the hyperbranched starch and the film forming agent are mutually crossed in the mixing process to form a mutual transmission network structure, so that more bonding sites are exposed, and the bonding performance after film forming is greatly improved.
The synergist disclosed by the invention is a nonionic surfactant and a zwitterionic surfactant, has higher HLB value and stronger hydrophilicity, can be mutually combined and carried with a disinfectant and a healing agent through Van der Waals force, and effectively avoids volatilization of substances such as iodine and essential oil, so that disinfection components and healing components are arranged in a film, the disinfection and sterilization performance is improved, and the disinfection and sterilization function also has a certain slow release property, prevents infection and promotes healing. The synergist can also cooperate with the adhesive to greatly improve the wettability and permeability of the film forming agent, so that the liquid adhesive bandage can be rapidly spread on the skin, and the extensibility is better, thereby being capable of forming films more rapidly.
The film forming agent adopts the ammonium polymethacrylate or the ammonium polymethacrylate and has certain air permeability. And then adding a surfactant, wherein the surfactant can ensure that the whole formed film has air permeability and moisture permeability, protect the skin and ensure the normal respiration and metabolism of the skin.
The invention also discloses a preparation method of the liquid adhesive bandage, which comprises the following steps:
(1) Adding a solvent and a plasticizer into a reaction kettle, fully mixing, slowly adding a film forming agent, and stirring until the film forming agent is completely dissolved;
(2) And (3) fully mixing the disinfectant, the healing agent, the anti-sticking agent, the adhesive and the synergist, then adding the mixture into the reaction kettle in the step (1), and fully stirring to obtain the liquid adhesive bandage.
The invention also provides application of the liquid adhesive bandage, which is used for skin surface wounds of human bodies, and also can be used for skin, hooves, paws, knees, tail ends, ears, navel or scrotum of different animals (pigs, cows, sheep, horses and the like).
The liquid adhesive bandage and the preparation method have the beneficial effects that:
(1) The liquid adhesive bandage disclosed by the invention has good stability, the formula is not affected by temperature, the liquid adhesive bandage can resist high temperature of 60 ℃ and low temperature of minus 30 ℃, the content of disinfection components in the prepared liquid adhesive bandage is placed for 2 years at room temperature, the reduction rate is not more than 3%, and the liquid adhesive bandage can be stably stored.
(2) The film forming agent selected by the liquid adhesive bandage can quickly generate a layer of breathable waterproof film which is tightly attached to the skin at a using position, meanwhile, the plasticizer is added, the elasticity and toughness of the film are improved, the distortion resistance is high in the moving process of people or animals, the adhesive bandage film is not cracked due to actions, the skin friendly adhesive is added, the film forming viscosity is greatly improved, the falling off is prevented, the film forming agent does not have dry and tight feel after being used, and compared with products on the market, the film forming agent has high film forming speed, and has better flex resistance, cohesiveness, water resistance, air permeability, sterilization property and bacteria resistance.
(3) The formula of the invention is added with substances for promoting wound healing, which is beneficial to wound healing.
(4) The invention has less pain feeling and no pungent and peculiar smell in the use process, and has high comfort level.
(5) The application range is wide: is not limited by the shape and position of the wound, and is suitable for wounds with various sizes.
Detailed Description
In order that the manner in which the invention may be better understood, a more particular description of the invention will be rendered by reference to specific embodiments thereof which are illustrated in the appended drawings. All other embodiments, which can be made by those skilled in the art based on the embodiments of the invention without making any inventive effort, are intended to be within the scope of the invention.
A liquid adhesive bandage comprises 5-15 parts of film forming agent, 0.1-5 parts of disinfectant, 0-5 parts of plasticizer, 0-3 parts of anti-adhesion agent, 1-5 parts of healing agent, 0.1-0.5 part of adhesive, 0.01-0.05 part of synergist, 0-0.5 part of pigment and the balance of solvent.
The film forming agent is one or more of ammonium methacrylate I, ammonium methacrylate II, polyacrylic resin III, polyvinylpyrrolidone K15, polyvinylpyrrolidone K30, polyvinylpyrrolidone K60, polyvinyl alcohol 05-88, polyvinyl alcohol 17-88, polyvinyl alcohol 124, polyvinyl formal, polyvinyl butyral, methylcellulose, hydroxypropyl methylcellulose, hydroxyethyl cellulose, carboxymethyl cellulose, nitrocellulose, xanthan gum, guar gum and shellac.
The disinfectant comprises one or more of iodine, triclosan, parachlorometaxylenol, chlorocresol, hexachlorophenol, polyhexamethylene biguanide hydrochloride, chlorhexidine, benzalkonium chloride, benzalkonium bromide, decamethenamine chloride, decamethenamine bromide and domiphen bromide.
The above healing agent is one or more of cajeput oil, benzyl alcohol, bisabolol, tea tree oil, essential oil of flos Inulae, oleum Eucalypti, notoginseng radix, lignum Dalbergiae Odoriferae, allantoin, vitamin A, and zinc chelate.
In the conventional art, iodine in the disinfectant, bisabolol in the healing agent, essential oil, and the like are generally carried with a substance having good stability such as guanidine antibacterial agent or antibiotic, because of the easy volatilization and loss of drug properties. By adding the synergistic agent, the surfactant and the specific film forming agent, the invention can realize synergistic effect, so that the medicine is more stable and not easy to decompose, and the medicine effect and the shelf life are prolonged.
The synergistic agent is polyoxyethylene polyoxypropylene ether segmented copolymer, polyoxyethylene fatty acid or erucamide betaine or a mixture of any one or more of polyoxyethylene fatty acid and erucamide betaine. Wherein the polyoxyethylene polyoxypropylene ether segmented copolymer is any one of poloxamer 124, poloxamer 188 and poloxamer 237.
It is worth noting that the ammonium polymethacrylate I is insoluble in isopropanol. Is obtained by copolymerizing methyl methacrylate, ethyl acrylate and trimethylammonium ethyl methacrylate in a ratio of 60:30:10. In the prior art, the ammonium polymethacrylate I is mainly used as a functional carrier of a medicament, such as a coating material and a release retarder for the medicament as a slow-release pharmaceutical auxiliary material. The added ammonium polymethacrylate I can carry medicines, improve the medicine effect of the liquid adhesive bandage, have certain viscosity, and are matched with polyacrylic resin in the film forming agent to improve the medicine effect.
It is worth noting that the poly (ammonium methacrylate) II, methyl methacrylate, ethyl acrylate and trimethylammoniumethyl methacrylate are obtained by copolymerization in a ratio of 65:30:5. The added ammonium polymethacrylate II can carry medicines, improve the medicine effect of the liquid adhesive bandage, has certain viscosity, and can be matched with polyacrylic resin in the film forming agent to improve the medicine effect.
The adhesive comprises any one or more of gelatin, dopamine, starch, cellulose and hyperbranched polyglycidyl ether, wherein the starch is hyperbranched starch.
Gelatin is a thin sheet or powder of white or yellowish, semitransparent, slightly glossy, or slightly glossy collagen in connective tissue such as animal skin, bone, myomembrane, and muscle charm. Has good compatibility with human or animal skin, and can be used for adhesion.
It is worth to say that dopamine is added as adhesive, and mixed with gelatin and starch, so that it has high adhesion and good compatibility with human body, and thus it has also wound recovering function.
It is worth to say that the starch is hyperbranched starch, the viscosity is better, and the cohesiveness is enhanced after the starch is mixed and crosslinked with gelatin and dopamine. Meanwhile, the dopamine has higher air permeability and tensile strength, better air permeability and better winding-resistant area, and is not easy to fall off after film formation.
Example 1
A liquid adhesive bandage comprises 10 parts of polyacrylic resin II, 3 parts of chlorocresol, 3 parts of plasticizer triethyl citrate, 3 parts of magnesium stearate, 2 parts of benzyl alcohol, 3 parts of tea tree oil, 0.3 part of adhesive, 0.02 part of erucamide betaine, 0.1 part of brilliant blue pigment and the balance of solvent, wherein the solvent is ethanol and water mixed according to the proportion of 6:1.
Wherein the adhesive is prepared by mixing gelatin, dopamine and hyperbranched starch according to the ratio of 4:0.5:1.
Example 2
A liquid adhesive bandage comprises 7 parts of polyacrylic resin II, 3 parts of ammonium methacrylate I, 3 parts of chlorocresol, 3 parts of plasticizer triethyl citrate, 3 parts of magnesium stearate, 2 parts of benzyl alcohol, 3 parts of tea tree oil, 0.1 part of adhesive, 0.01 part of erucamide betaine, 0.1 part of brilliant blue pigment and the balance of solvent, wherein the solvent is ethanol and water mixed according to the proportion of 6:1.
Wherein the adhesive is prepared by mixing gelatin, dopamine and hyperbranched starch according to the ratio of 4:0.5:1.
Example 3
The liquid adhesive bandage comprises 10 parts of polyacrylic resin II, 1 part of benzalkonium chloride, 3 parts of plasticizer triethyl citrate, 3 parts of magnesium stearate, 2 parts of benzyl alcohol, 3 parts of tea tree oil, 0.2 part of adhesive, 0.01 part of erucamide betaine, 0.1 part of brilliant blue pigment and the balance of solvent, wherein the solvent is ethanol and water mixed according to the proportion of 6:1.
Wherein the adhesive is prepared by mixing gelatin, dopamine and hyperbranched starch according to the ratio of 4:0.5:1.
Example 4
The liquid adhesive bandage comprises 10 parts of polyacrylic resin III, 5 parts of ammonium polymethacrylate II, 2 parts of iodine, 3 parts of povidone iodine, 3 parts of plasticizer glyceryl triacetate, 3 parts of micro powder silica gel, 3 parts of tea tree oil, 0.5 part of adhesive, 0.05 part of acrylamide sulfobetaine, 0.1 part of brilliant blue pigment and the balance of solvent, wherein the solvent is isooctane and ethanol which are mixed according to a ratio of 1:5.
Wherein the adhesive is prepared by mixing gelatin, dopamine and hyperbranched starch according to the ratio of 4:0.5:1.
Example 5
The liquid adhesive bandage comprises 10 parts of polyacrylic resin III, 3 parts of carboxymethyl cellulose, 2 parts of iodine, 3 parts of povidone iodine, 3 parts of plasticizer glyceryl triacetate, 3 parts of micro silica gel, 2 parts of benzyl alcohol, 3 parts of tea tree oil, 0.5 part of adhesive, 0.05 part of poloxamer 124, 0.1 part of brilliant blue pigment and the balance of solvent, wherein the solvent is isooctane and ethanol which are mixed according to a ratio of 1:10.
Wherein the adhesive is prepared by mixing gelatin, dopamine and hyperbranched starch according to the ratio of 4:1:2.
Example 6
The liquid adhesive bandage comprises 10 parts of polyacrylic resin III, 3 parts of hydroxyethyl cellulose, 2 parts of iodine, 3 parts of povidone iodine, 3 parts of plasticizer glyceryl triacetate, 3 parts of micro silica gel, 2 parts of benzyl alcohol, 3 parts of tea tree oil, 0.5 part of adhesive, 0.05 part of polyoxyethylene fatty acid, 0.1 part of brilliant blue pigment and the balance of solvent, wherein the solvent is ethanol and water mixed according to a ratio of 6:1.
Wherein the adhesive is prepared by mixing gelatin, dopamine and hyperbranched starch according to the proportion of 4:0.5:2.
Example 7
The liquid adhesive bandage comprises 10 parts of polyacrylic resin III, 3 parts of carboxymethyl cellulose, 2 parts of iodine, 3 parts of povidone iodine, 3 parts of plasticizer glyceryl triacetate, 3 parts of micro silica gel, 2 parts of benzyl alcohol, 3 parts of tea tree oil, 0.5 part of adhesive, 0.05 part of erucamide betaine, 0.1 part of brilliant blue pigment and the balance of solvent, wherein the solvent is isooctane and ethanol which are mixed according to a ratio of 1:8.
Wherein the adhesive is prepared by mixing gelatin, dopamine and hyperbranched starch according to the proportion of 4:0.5:1.5.
Example 8
The liquid adhesive bandage comprises 10 parts of polyacrylic resin III, 1 part of ammonium polymethacrylate II, 2 parts of benzalkonium bromide, 3 parts of plasticizer glyceryl triacetate, 3 parts of micro silica gel, 2 parts of benzyl alcohol, 3 parts of tea tree oil, 0.5 part of adhesive, 0.05 part of acrylamide sulfobetaine, 0.1 part of brilliant blue pigment and the balance of solvent, wherein the solvent is isooctane and ethanol which are mixed according to the proportion of 1:3.
Wherein the adhesive is prepared by mixing gelatin, dopamine and hyperbranched starch according to the ratio of 4:0.5:1.
Example 9
The liquid adhesive bandage comprises 10 parts of polyacrylic resin III, 1 part of ammonium polymethacrylate II, 2 parts of benzalkonium bromide, 3 parts of plasticizer glyceryl triacetate, 3 parts of micro silica gel, 2 parts of benzyl alcohol, 3 parts of tea tree oil, 0.5 part of adhesive, 0.05 part of poloxamer 188, 0.1 part of brilliant blue pigment and the balance of solvent, wherein the solvent is hexamethyldisiloxane and ethanol according to a ratio of 1:10.
Wherein the adhesive is prepared by mixing gelatin, dopamine and hyperbranched starch according to the ratio of 4:1:2.
Example 10
The liquid adhesive bandage comprises 10 parts of polyacrylic resin III, 1 part of ammonium polymethacrylate II, 2 parts of benzalkonium bromide, 3 parts of plasticizer glyceryl triacetate, 3 parts of micro silica gel, 2 parts of benzyl alcohol, 3 parts of tea tree oil, 0.5 part of adhesive, 0.05 part of polyoxyethylene fatty acid, 0.1 part of brilliant blue pigment and the balance of solvent, wherein the solvent is hexamethyldisiloxane and ethanol according to a ratio of 1:8.
Wherein the adhesive is prepared by mixing gelatin, dopamine and hyperbranched starch according to the proportion of 4:0.5:2.
Example 11
The liquid adhesive bandage comprises 10 parts of polyacrylic resin III, 1 part of ammonium polymethacrylate II, 2 parts of benzalkonium bromide, 3 parts of plasticizer glyceryl triacetate, 3 parts of micro silica gel, 2 parts of benzyl alcohol, 3 parts of tea tree oil, 0.5 part of adhesive, 0.05 part of erucamide betaine, 0.1 part of brilliant blue pigment and the balance of solvent, wherein the solvent is ethanol and water mixed according to a ratio of 6:1.
Wherein the adhesive is prepared by mixing gelatin, dopamine and hyperbranched starch according to the proportion of 4:0.5:1.5.
Example 12
The liquid adhesive bandage comprises 10 parts of polyacrylic resin III, 1 part of ammonium polymethacrylate II, 2 parts of decamethylene bromide, 3 parts of plasticizer glyceryl triacetate, 3 parts of micro silica gel, 2 parts of benzyl alcohol, 3 parts of tea tree oil, 0.5 part of adhesive, 0.05 part of acrylamide sulfobetaine, 0.1 part of brilliant blue pigment and the balance of solvent, wherein the solvent is hexamethyldisiloxane and ethanol according to a ratio of 1:5.
Wherein the adhesive is prepared by mixing gelatin, dopamine and hyperbranched starch according to the ratio of 4:0.5:1.
Example 13
The liquid adhesive bandage comprises 10 parts of polyacrylic resin III, 1 part of ammonium polymethacrylate II, 2 parts of decamethylene bromide, 3 parts of plasticizer glyceryl triacetate, 3 parts of micro silica gel, 2 parts of benzyl alcohol, 3 parts of tea tree oil, 0.5 part of adhesive, 0.05 part of poloxamer 188, 0.1 part of brilliant blue pigment and the balance of solvent, wherein the solvent is hexamethyldisiloxane and ethanol according to a ratio of 1:8.
Wherein the adhesive is prepared by mixing gelatin, dopamine and hyperbranched starch according to the ratio of 4:1:2.
Example 14
The liquid adhesive bandage comprises 10 parts of polyacrylic resin III, 1 part of ammonium polymethacrylate II, 2 parts of decamethylene bromide, 3 parts of plasticizer glyceryl triacetate, 3 parts of micro silica gel, 2 parts of benzyl alcohol, 3 parts of tea tree oil, 0.5 part of adhesive, 0.05 part of polyoxyethylene fatty acid, 0.1 part of brilliant blue pigment and the balance of solvent, wherein the solvent is ethanol and water mixed according to the proportion of 7:1.
Wherein the adhesive is prepared by mixing gelatin, dopamine and hyperbranched starch according to the proportion of 4:0.5:2.
Example 15
The liquid adhesive bandage comprises 10 parts of polyacrylic resin III, 1 part of ammonium polymethacrylate II, 2 parts of decamethylene bromide, 3 parts of plasticizer glyceryl triacetate, 3 parts of micro silica gel, 2 parts of benzyl alcohol, 3 parts of tea tree oil, 0.5 part of adhesive, 0.05 part of erucamide betaine, 0.1 part of brilliant blue pigment and the balance of solvent, wherein the solvent is ethanol and water mixed according to the proportion of 7:1.
Wherein the adhesive is prepared by mixing gelatin, dopamine and hyperbranched starch according to the proportion of 4:0.5:1.5.
Example 16
The hoof disease liquid adhesive bandage for the dairy cows comprises 12 parts of polyacrylic resin III, 3 parts of ammonium polymethacrylate II, 5 parts of chlorocresol, 3 parts of plasticizer glyceryl triacetate, 3 parts of micro silica gel, 2 parts of benzyl alcohol, 3 parts of tea tree oil, 0.5 part of adhesive, 0.05 part of erucamide betaine, 0.1 part of brilliant blue pigment and the balance of solvent, wherein the solvent is ethanol and water mixed according to the proportion of 7:1.
Wherein the adhesive is prepared by mixing gelatin, dopamine and hyperbranched starch according to the proportion of 4:0.5:1.5.
Example 17
The liquid adhesive bandage for the skin wounds of the human body comprises 12 parts of polyacrylic resin III, 1 part of ammonium polymethacrylate II, 1 part of benzalkonium chloride, 3 parts of plasticizer glyceryl triacetate, 3 parts of micro powder silica gel, 2 parts of benzyl alcohol, 3 parts of tea tree oil, 0.5 part of adhesive, 0.05 part of erucamide betaine, 0.1 part of brilliant blue pigment and the balance of solvent, wherein the solvent is ethanol and water which are mixed according to the proportion of 6.5:1.
Wherein the adhesive is prepared by mixing gelatin, dopamine and hyperbranched starch according to the proportion of 4:0.5:1.5.
Example 18
A method of preparing a liquid wound covering comprising the steps of:
(1) Adding a solvent and a plasticizer into a reaction kettle, fully mixing, slowly adding a film forming agent, and stirring until the film forming agent is completely dissolved;
(2) And (3) fully mixing the disinfectant, the healing agent, the anti-sticking agent, the adhesive and the synergist, then adding the mixture into the reaction kettle in the step (1), and fully stirring for 30-60 minutes to obtain the liquid adhesive bandage.
Example 19
The application method of the liquid wound plaster comprises the following steps:
the method comprises the following steps: placing the sample into a spray can or spray bottle, uniformly spraying at 15-20 cm distance of the required position, waiting for 0.5-3 min, and drying the surface.
The second method is as follows: uniformly smearing the sample on a part to be used, waiting for 0.5-3 minutes, and drying the surface.
Comparative example 1
The same components as in example 1 except that no adhesive was added.
Comparative example 2
The same ingredients as in example 1 except that no dopamine was added to the adhesive, gelatin was mixed with hyperbranched starch in a ratio of 4:1.5.
Comparative example 3
The same components as in example 1 except that no hyperbranched starch was added to the adhesive, gelatin and dopamine were mixed in a ratio of 4:0.5.
Comparative example 4
The same components as in example 1 except that dopamine and hyperbranched starch were not added to the adhesive.
Comparative example 5
The same ingredients as in example 1 except that no synergist was added.
1. Stability test
Examples 1-17 were left for 0, 5, 10, 30 days at a temperature of 60.+ -. 2 ℃ and a relative humidity of 20.+ -. 10%, and the content of the main component (disinfectant) was examined, and the results of the laboratory tests are shown in Table 1:
TABLE 1 disinfectant content (%)
As can be seen from Table 1, the invention has good stability, and the disinfectant content in the liquid is little changed and basically tends to be stable when the disinfectant is placed for 30 days at the temperature of 60 ℃.
2. Film formation time
Examples 1 to 3, examples 4, 8, 12, 16, 17 and comparative examples 1 to 5 were applied to the epidermis of the skin using 0.1g of the sample to form a film having a length of 2cm and a width of 1cm, and the film formation change was observed, and the results are shown in Table 2:
table 2 film formation time(s) of each component
| Group of | Film formation(s) starts to appear | Completely drying film(s) |
| Example 1 | 8 | 35 |
| Example 2 | 10 | 37 |
| Example 3 | 8 | 35 |
| Example 4 | 10 | 37 |
| Example 8 | 9 | 36 |
| Example 12 | 12 | 35 |
| Example 16 | 10 | 40 |
| Example 17 | 12 | 35 |
| Comparative example 1 | 15 | 50 |
| Comparative example 2 | 15 | 45 |
| Comparative example 3 | 15 | 60 |
| Comparative example 4 | 15 | 55 |
| Comparative example 5 | 30 | 80 |
As can be seen from Table 2, the film drying time of the examples of the present invention was within 30-40s, and the film forming time in the comparative examples was between 60-80s, and the film formation of the present invention was faster.
3. Characterization of breathability and cohesiveness Properties
The falling time detection method comprises the following steps: 0.1g of the sample is uniformly sprayed or smeared on the skin to form a film to start timing until the film is peeled off.
Elongation detection criteria: GB/T7753-1987;
tensile strength test standard: GB/T7753-1987;
air permeability detection standard: YY/T0471.2-2004;
water resistance detection standard: YY/T0471.3-2004;
the results are shown in Table 3:
table 3 Properties of each group
As can be seen from Table 3, the tensile strength is generally greater in the examples of the present invention than in the comparative examples 1 to 5, while the falling time is longer in the examples 1 to 17, indicating the better adhesion of the present invention from the side.
The air permeability refers to the difficulty of allowing the gas to pass through the solid bulk material layer, and the larger the air quantity passing through the material layer in unit time is, the better the air permeability of the film is. The MVTR values (air permeability) of examples 1-17 are greater, while the MVTR values of comparative examples 1-5 are less, and therefore the air permeability of the present invention is better than that of comparative examples 1-5. Namely, the invention has obvious effect of improving the air permeability of the adhesive bandage.
In addition, as can be seen from comparative examples 1, 2, 3 and 4, the adhesive was not added in comparative example 1, and the adhesive lacking components was added in each of comparative examples 2, 3 and 4, and the air permeability of comparative example 1 was significantly inferior to that of comparative examples 2, 3 and 4, indicating that the adhesive of the present invention can promote air permeability.
By comparing the comparative examples 2, 3 and 4 with the examples, it can be demonstrated that the adhesive of the invention has a synergistic effect by specific components and proportions, and the air permeability and cohesiveness of the product are greatly improved.
Comparative example 5 shows that the synergist of the present invention has a certain promoting effect on air permeability as compared with the examples.
As can be seen from table 3, the adhesive and the synergist of the present invention can effectively improve the air permeability of the adhesive bandage film and promote the respiration of the epidermal cells, thereby accelerating the healing.
4. Tack Performance test
Peel force test: the adhesive strength of the film was measured by a texture analyzer and a 90 degree peel test method, and the liquid was sprayed 3 times on the glass surface, dried to form a film sample having a length of 5cm and a width of 1cm, and the film sample was tested by a standard 90 degree peel test method, with a set peel speed of 5mm/min. The data obtained are shown in table 4:
table 4 adhesive and peel strength of each group
| Group of | Adhesive Strength (N/m) | Maximum peel strength (N/m) |
| Example 1 | 54.6 | 155.3 |
| Example 2 | 46.7 | 148.2 |
| Example 3 | 48.5 | 152.6 |
| Example 4 | 63.4 | 183.7 |
| Example 8 | 60.5 | 167.9 |
| Example 12 | 61.3 | 176.5 |
| Example 16 | 59.4 | 164.8 |
| Example 17 | 58.7 | 159.7 |
| Comparative example 1 | 34.6 | 128.7 |
| Comparative example 2 | 39.2 | 138.5 |
| Comparative example 3 | 38.7 | 134.7 |
| Comparative example 4 | 36.9 | 132.6 |
| Comparative example 5 | 47.8 | 150.6 |
As can be seen from Table 4, the adhesive strength of the examples of the present invention was higher, indicating that the adhesiveness of the present invention was better.
5. Sterilization performance test
Reference basis: disinfection technical Specification (2002 edition), GB/T38504-2020 method for evaluating spray Disinfection Effect.
Detecting strains: coli (8099); staphylococcus aureus (ATCC 6538); candida albicans (ATCC 16404); pseudomonas aeruginosa (ATCC 15442).
The testing method comprises the following steps:
after the carrier is sterilized by pressure steam, the carrier is stained by a drop-staining method, and the steps comprise:
(1) bacterial suspension for bacterial infection: taking fresh slant culture of active bacteria, adding 5mL of sterile TPS diluent into the culture medium of inoculated bacteria, eluting the lawn, simultaneously immediately transferring the lotion into a 10-mL round bottom continuous sterile centrifuge tube, shaking and mixing for about 30s to a uniform state, and diluting until the concentration of bacterial suspension is about 1X 108cfu/mL to 5X 108cfu/mL.
(2) The sterilized carrier is spread in a disposable sterile culture dish, a 10 mu l pipette is connected with a sterilized plastic suction head to suck the bacterial suspension for liquid-dyeing, and the dripping amount of the bacterial suspension is 10 mu l for each tablet. After the bacterial liquid is dripped, the bacterial carrier can be dried in a temperature box at 37 ℃ for about 20 to 30 minutes or naturally dried in the shade at room temperature for about 20 minutes for reuse.
(3) The method comprises the steps of respectively putting the bacterial-dyeing carriers into TPS, using TPS as 10-time serial dilution, selecting proper concentration for viable bacteria technology culture, and counting the number of recovered bacteria of each bacterial sheet according to viable bacteria culture, wherein the result is 5 multiplied by 105 cfu/sheet to 5 multiplied by 106 cfu/sheet.
The disinfectant and 3 action times (1 min, 3min, 5 min) were selected for the test. Each bacterial sheet should be tested separately. In the test, 3 carrier fungus sheets are respectively taken and uniformly distributed in a disposable sterile culture dish which is not stained with any disinfectant in an equilateral triangle or triangle array.
Each batch of test was conducted with uniform spraying of the bacterial flakes of the above arrangement with the same concentration of disinfectant solution. The distance and pressure of each spraying are kept consistent, so that the size and the number of fog particles sprayed on the fungus flakes are consistent as much as possible. The spraying amount is enough to prevent the bacterial flakes from wetting out and flowing liquid.
After the bacteria tablet interacts with the disinfectant for each prescribed time, immediately taking the carrier bacteria tablet, and placing each into a 10ml round bottom continuous cover sterile centrifuge tube (or a sterile test tube) filled with 5.0ml sterile neutralizing agent. The test tube was mixed with an electric mixer for 20s or shaken on the palm 80 times to allow colonies on the plaque to elute into the neutralization solution. 1.0ml of the above-mentioned washing liquid was aspirated, and the number of viable bacteria was measured by the viable bacteria culture counting method, and the plate was inoculated.
Each batch should be replaced with a clean sterile petri dish without any disinfectant. Before replacing the sprayer with the disinfectant with new concentration, the original disinfectant should be cleaned and replaced with the disinfectant with new concentration.
The same spray method was used to treat the positive control group instead of disinfectant with hard water. If the aerosol disinfectant is a pressure canned automatic spray aerosol disinfectant, the carrier can be directly used as a live bacteria count to be used as a positive control group before treatment.
All test samples are cultivated in a constant temperature box at 36+/-1 ℃ and the final result is observed after 24-48 hours of bacterial propagule cultivation; the final results were observed for Candida albicans cultures for 36-48 h.
The test was repeated 3 times, the viable count (cfu/sheet) of each group was calculated and converted to a logarithmic value (N), and then the killing logarithmic value was calculated as follows:
log value of killing log value (KL) =log value of average viable bacteria concentration of control group (No) -log value of viable bacteria concentration of test group (Nx)
Evaluation rules for quantitative sterilization tests
The product supervision test was repeated 3 times at the minimum concentration and minimum duration of action specified in the product specification. The quantitative killing test of the carrier is required, the killing logarithmic value of each time is more than or equal to 3.00, and the disinfection qualification can be judged.
In the product declaration sanitary approval test, the test is repeated 3 times at the concentration and the action time specified in the product specification. At the product specified minimum concentration and minimum time of action, and 1.5 times the minimum time of action. In the quantitative carrier killing test, the number of the killing numbers of each time is more than or equal to 3.00, and the disinfection is qualified. The data obtained by the test are shown in Table 5:
table 5 Sterilization effects of each group
Note that: * Indicating too many to count, the negative control grew aseptically, and the positive control colonies were too many to count.
As can be seen from Table 5, the products obtained by the invention have good bactericidal effect.
6. Bacteria resistance test
Reference basis: YY/T0471.5-2004 section 5 of the contact wound dressing test method: bacteria resistance.
Detecting strains: coli (8099); staphylococcus aureus (ATCC 6538); candida albicans (ATCC 16404); pseudomonas aeruginosa (ATCC 15442).
Test conditions: testing under low moisture and semi-humid conditions.
Culturing in a constant temperature incubator at 36+ -1deg.C for 24-48 hr, and observing colony growth. The results obtained are shown in Table 6:
TABLE 6 bacterial resistance test
7. Skin irritation test
Skin irritation detection criteria: 2002 edition of disinfectant technical Specification
Table 7 skin irritation test grade
Reference herein to "an embodiment" means that a particular feature, structure, or characteristic described in connection with the embodiment may be included in at least one embodiment of the invention. The appearances of such phrases in various places in the specification are not necessarily all referring to the same embodiment, nor are separate or alternative embodiments mutually exclusive of other embodiments. Those of skill in the art will explicitly and implicitly appreciate that the embodiments described herein may be combined with other embodiments.
Finally, it should be noted that: the embodiment of the invention is disclosed only as a preferred embodiment of the invention, and is only used for illustrating the technical scheme of the invention, but not limiting the technical scheme; although the invention has been described in detail with reference to the foregoing embodiments, those of ordinary skill in the art will understand that; the technical scheme recorded in the various embodiments can be modified or part of technical features in the technical scheme can be replaced equivalently; such modifications and substitutions do not depart from the spirit and scope of the corresponding technical solutions.
Claims (9)
1. A liquid wound dressing, characterized in that: comprises 5-15 parts of film forming agent, 0.1-5 parts of disinfectant, 0-5 parts of plasticizer, 0-3 parts of anti-adhesion agent, 1-5 parts of healing agent, 0.1-0.5 part of adhesive, 0.01-0.05 part of synergist, 0-0.5 part of pigment and the balance of solvent.
2. The liquid wound covering of claim 1, wherein: the film forming agent is one or more of ammonium methacrylate I, ammonium methacrylate II, polyacrylic resin III, polyvinylpyrrolidone K15, polyvinylpyrrolidone K30, polyvinylpyrrolidone K60, polyvinyl alcohol 05-88, polyvinyl alcohol 17-88, polyvinyl alcohol 124, polyvinyl formal, polyvinyl butyral, methylcellulose, hydroxypropyl methylcellulose, hydroxyethyl cellulose, carboxymethyl cellulose, nitrocellulose, xanthan gum, guar gum and shellac.
3. The liquid wound covering of claim 1, wherein: the disinfectant comprises one or more of iodine, triclosan, parachlorometaxylenol, chlorocresol, hexachlorophenol, polyhexamethylene monoguanidine hydrochloride, polyhexamethylene biguanide hydrochloride, chlorhexidine, benzalkonium chloride, benzalkonium bromide, decamethenamine chloride, decamethenamine bromide and domiphen bromide.
4. The liquid wound covering of claim 1, wherein: the plasticizer is one or more of triethyl citrate, glyceryl triacetate, acetyl tributyl citrate, dioctyl adipate, diethyl phthalate, dibutyl phthalate, dioctyl phthalate, butyl Jizhi phthalate, di-n-octyl phthalate and polyethyl phenylmethyl siloxane.
5. The liquid wound covering of claim 1, wherein: the healing agent is one or more of cajeput oil, benzyl alcohol, bisabolol, tea tree oil, essential oil of permanent flowers, eucalyptus oil, pseudo-ginseng, rosewood heart wood, allantoin, vitamin A and chelated zinc.
6. The liquid wound covering of claim 1, wherein: the anti-sticking agent is one or more of talcum powder, magnesium stearate, micro-powder silica gel and glyceryl stearate.
7. The liquid wound covering of claim 1, wherein: the synergistic agent is any one or a mixture of more than one of polyoxyethylene polyoxypropylene ether segmented copolymer, polyoxyethylene fatty acid and erucamide betaine.
8. The liquid wound covering of claim 7, wherein: the average molecular weight of the polyoxyethylene polyoxypropylene ether block copolymer is 1100-11000.
9. A method of preparing a liquid wound covering as claimed in any one of claims 1 to 8, characterised in that: the method comprises the following steps:
(1) Adding a solvent and a plasticizer into a reaction kettle, fully mixing, slowly adding a film forming agent, and stirring until the film forming agent is completely dissolved;
(2) And (3) fully mixing the disinfectant, the healing agent, the anti-sticking agent, the adhesive and the synergist, then adding the mixture into the reaction kettle in the step (1), and fully stirring to obtain the liquid adhesive bandage.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211091707.9A CN116271199A (en) | 2022-09-07 | 2022-09-07 | Liquid adhesive bandage and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211091707.9A CN116271199A (en) | 2022-09-07 | 2022-09-07 | Liquid adhesive bandage and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116271199A true CN116271199A (en) | 2023-06-23 |
Family
ID=86826291
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211091707.9A Pending CN116271199A (en) | 2022-09-07 | 2022-09-07 | Liquid adhesive bandage and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116271199A (en) |
-
2022
- 2022-09-07 CN CN202211091707.9A patent/CN116271199A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7054212B2 (en) | A novel fast-adhesive thin-film forming composition as an effective wound care procedure | |
| CN104274490B (en) | Bactericidal composition including source of silver ions and menthol and application thereof | |
| CN107185031B (en) | A kind of biologically active medical dressing and preparation method thereof | |
| KR20060130199A (en) | Anti-infectious hydrogel compositions | |
| US20100120915A1 (en) | Antimicrobials and related methods | |
| EP1339282B1 (en) | Hydrophilic polymer blends used for dry cow therapy | |
| KR20190126302A (en) | Chitosan-containing formulations and methods of making and using the same | |
| JPH09165330A (en) | New skin preparation composition | |
| CN105168238A (en) | Hyaluronic temperature-sensitive gel and preparation method and application thereof | |
| CN101543658B (en) | Cervical cap for preventing and treating cervical erosion and preparation method thereof | |
| CN111991417A (en) | Hypochlorous acid gel with physiological responsiveness and application thereof in skin wound surface | |
| CN106267329B (en) | A kind of plants essential oil gel dressing and its preparation method and application | |
| RU2370259C1 (en) | Method of cow udder teat disease treatment in mechanised milking | |
| CN116271199A (en) | Liquid adhesive bandage and preparation method thereof | |
| CN106729962B (en) | Skin antibacterial protective film liquid and preparation method thereof | |
| US6537577B1 (en) | Method of prophylaxis for bovine mastitis | |
| CN109200326A (en) | Dressing and bandage for wound healing | |
| CN107595819B (en) | A kind of Nano diamond modified liquid adhesive bandage and preparation method thereof | |
| CN107753937A (en) | A kind of wound disinfection agent and preparation method thereof | |
| CN106236835A (en) | A kind of plants essential oil spray and its preparation method and application | |
| CN107174573B (en) | Preparation method of wound surface protective film spray | |
| CN112274690B (en) | Liquid dressing and preparation method thereof | |
| CS366289A2 (en) | Method of stable aqueous suspeoemulsions production | |
| CN115777725B (en) | Nano silver disinfectant and preparation method thereof | |
| RU2404751C2 (en) | Wound healing agent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |